AndroGel History and Development

Before AndroGel: The Problem With Early Testosterone Delivery

Testosterone replacement existed for decades before topical gels arrived, but every available option carried significant drawbacks that limited patient adherence and clinical outcomes.

Injectable Testosterone Era

Intramuscular testosterone cypionate and enanthate, introduced in the 1950s, produced wide pharmacokinetic swings. Patients experienced supraphysiological peaks within 48 to 72 hours of injection, followed by troughs that often dipped below the eugonadal range before the next dose. A 1986 pharmacokinetic study documented that testosterone cypionate 200 mg every two weeks generated peak-to-trough ratios exceeding 3:1 in most subjects 1. These fluctuations translated into cyclical mood changes, energy dips, and erratic libido.

Transdermal Patches and Their Limitations

The scrotal testosterone patch (Testoderm) reached the market in 1993, followed by the non-scrotal patch (Androderm) in 1995. Androderm improved convenience but caused application-site reactions in up to 60% of users according to its original registration data 2. Skin irritation led to discontinuation rates of 10% to 15% in clinical practice. The field needed a transdermal formulation with better tolerability. That gap defined the commercial opportunity Unimed Pharmaceuticals targeted in the mid-1990s.

How AndroGel Was Developed

Unimed Pharmaceuticals, a specialty pharma subsidiary, began developing a hydroalcoholic gel matrix for transdermal testosterone delivery in the early 1990s. The goal was straightforward: match the steady-state kinetics of patches without the adhesive-related skin reactions.

The Hydroalcoholic Gel Platform

The formulation uses ethanol and isopropyl myristate as penetration enhancers dissolved in a carbomer gel base. When applied to intact skin on the shoulders, upper arms, or abdomen, the alcohol evaporates within two to five minutes, leaving a thin testosterone-loaded film. Testosterone then permeates the stratum corneum via passive diffusion into the dermal microvasculature. The skin itself acts as a reservoir, releasing testosterone into systemic circulation over approximately 24 hours.

Key Registration Trial

The phase III registration study enrolled 227 hypogonadal men randomized to AndroGel 5 g/day (50 mg testosterone), AndroGel 10 g/day (100 mg testosterone), or the Androderm patch. At 90 days, 87% of men on the 10 g dose achieved mean serum testosterone in the normal range (300 to 1,000 ng/dL), compared to 71% on the 5 g dose and 52% on the patch 3. Application-site reactions occurred in only 5.5% of gel users versus 66% of patch users. The data package supported FDA approval on February 28, 2000, making AndroGel the first testosterone gel approved in the United States.

FDA Approval and Early Market Uptake (2000 to 2005)

The FDA granted approval for AndroGel 1% (testosterone gel) under NDA 21-015 for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone 4.

Rapid Commercial Adoption

Prescriptions grew sharply. Testosterone prescriptions in the U.S. Rose from roughly 1.75 million in 2002 to 2.3 million by 2005, with topical gels capturing an increasing share from injectables. AndroGel drove much of this shift. Physicians and patients preferred a once-daily, painless application over biweekly intramuscular injections. By 2003, AndroGel held over 60% of the branded testosterone market.

Corporate Transitions

Solvay Pharmaceuticals acquired Unimed in 1999, gaining the AndroGel franchise just before approval. A decade later, in 2010, Abbott Laboratories purchased Solvay's pharmaceutical division for $6.6 billion, with AndroGel identified as a primary asset. When Abbott split into two companies in 2013, AndroGel transferred to the research-driven pharmaceutical arm: AbbVie. Each corporate transition reflected the product's revenue importance.

AndroGel 1.62%: The Reformulation (2011)

AbbVie (then Abbott) filed a supplemental NDA for a concentrated 1.62% formulation approved in October 2011. The reformulation served two purposes: clinical optimization and patent lifecycle extension.

What Changed in the Formulation

The 1.62% gel delivers the same testosterone dose in a smaller volume, reducing the surface area needed for application. Patients apply 20.25 mg to 81 mg of testosterone daily (1 to 4 pump actuations). Bioequivalence studies demonstrated comparable steady-state testosterone levels between the two formulations at dose-adjusted volumes. The smaller application footprint reduced the risk of secondary transfer to household contacts, a concern the FDA had flagged with increasing urgency.

The Black Box Warning

In 2009, the FDA mandated a boxed warning on all testosterone gels after reports of virilization in children exposed through skin-to-skin contact with treated adults. Cases included genital enlargement, premature pubic hair, and advanced bone age in children as young as nine months 5. The 1.62% formulation's smaller application area and faster drying time were partially positioned as risk-mitigation features, though the black box warning applied to both concentrations.

The Testosterone Trials (T-Trials): The Landmark Study

The T-Trials represent the most rigorous evidence base for topical testosterone therapy in older men. This coordinated set of seven placebo-controlled trials, funded by the National Institute on Aging and conducted at 12 U.S. Sites, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism 6.

Study Design

All participants received AndroGel 1% with dose titration targeting serum testosterone in the mid-normal range for young men (19 to 40 years). The seven component trials measured outcomes across sexual function, physical function, vitality, cognition, bone density, anemia, and cardiovascular risk. Treatment duration was 12 months.

Key Findings

The sexual function trial reported that testosterone treatment increased sexual activity scores by 0.58 points on a standardized questionnaire (P<0.001 vs. Placebo) and sexual desire by 0.41 points 6. The physical function trial found a modest but statistically significant improvement in 6-minute walking distance (an increase of approximately 6 meters). Vitality scores improved on the FACIT-Fatigue scale by 2.41 points, a difference that reached statistical significance but fell below the threshold most researchers consider clinically meaningful.

What the T-Trials Did Not Show

Cognitive function showed no improvement. The cardiovascular safety substudy found increased coronary artery plaque volume in the testosterone group on CT angiography, raising concern rather than providing reassurance 7. This finding contributed to the ongoing FDA-mandated cardiovascular outcome trial (TRAVERSE), which later reported that testosterone was non-inferior to placebo for major adverse cardiovascular events in men with preexisting or high risk of cardiovascular disease 8.

How AndroGel Works: Mechanism of Action

Testosterone delivered through the gel follows the same pharmacologic pathway as endogenous testosterone once it reaches the bloodstream.

Androgen Receptor Binding

Free testosterone crosses cell membranes and binds the intracellular androgen receptor (AR), a nuclear receptor that functions as a ligand-dependent transcription factor. The testosterone-AR complex dimerizes, translocates to the nucleus, and binds androgen response elements (AREs) on DNA, activating or repressing target gene transcription. Target tissues include skeletal muscle, bone, the central nervous system, erythropoietic tissue, and the male reproductive tract.

5-Alpha Reduction and Aromatization

A portion of circulating testosterone undergoes conversion to dihydrotestosterone (DHT) by 5-alpha reductase in skin, prostate, and other tissues. DHT binds the androgen receptor with roughly 2 to 3 times greater affinity than testosterone 9. Testosterone also serves as a substrate for aromatase (CYP19A1), which converts it to estradiol. Estradiol mediates bone mineral density maintenance in men, a point the Endocrine Society's 2018 clinical practice guideline emphasizes when monitoring testosterone therapy 10.

Pharmacokinetic Profile of the Gel

After the first application of AndroGel 1%, serum testosterone rises within 30 minutes and approaches steady state by day 2 to 3 of daily dosing. The Endocrine Society guideline recommends checking trough testosterone levels (drawn before the morning application) after at least one week, with the target range of 400 to 700 ng/dL for most patients 10.

Dr. Peter Snyder, principal investigator of the T-Trials and professor of medicine at the University of Pennsylvania, stated: "The T-Trials were designed to answer whether testosterone treatment of older men with low testosterone improved outcomes that matter most to them. The most consistent benefit was in sexual function" 6.

Patent Battles and Generic Competition

AndroGel's commercial trajectory cannot be separated from the patent litigation that defined its competitive environment for over a decade.

The Original 1% Patent Field

Unimed's original patents covering the 1% gel composition began expiring in 2010. Watson Pharmaceuticals (later Actavis) filed an ANDA and launched a generic 1% testosterone gel in late 2014. Perrigo followed. By 2015, multiple generic versions were available, and AndroGel 1% prescriptions shifted substantially toward generic alternatives.

The 1.62% Patent Extension Strategy

The reformulated 1.62% gel carried new composition-of-matter and method-of-use patents extending protection into the early 2020s. AbbVie pursued aggressive patent defense, filing suit against multiple ANDA filers including Teva, Actavis, and Perrigo. The Federal Trade Commission (FTC) investigated whether AbbVie's patent thicket constituted anticompetitive behavior. In 2014, the FTC alleged that AbbVie used sham patent litigation as part of an overarching scheme to maintain monopoly pricing 11. Legal proceedings continued through multiple circuits. Core formulation patents for the 1.62% product have since expired, though some method-of-use claims remained contested into 2024.

Revenue Impact

At its commercial peak in 2012, AndroGel generated approximately $1.15 billion in annual U.S. Revenue for AbbVie. By 2019, revenue had fallen below $250 million as generic competition and alternative branded gels (Testim, Vogelxo, Fortesta) eroded market share. The product's lifecycle illustrates a common pattern in specialty pharma: a dominant branded product with a reformulation extension followed by inevitable generic erosion.

Safety Controversies and the FDA's Evolving Stance

AndroGel's history includes two major safety controversies that reshaped the regulatory field for all testosterone products.

Cardiovascular Risk Debate

A 2010 trial in older men with mobility limitations (TOM trial, N=209) was stopped early when the testosterone group experienced a higher rate of cardiovascular adverse events (23 vs. 5 in placebo) 12. Two large observational studies in 2013 and 2014 suggested increased risk of myocardial infarction and stroke in testosterone users. The FDA issued a safety communication in 2015 requiring all testosterone products to carry a warning about possible cardiovascular risk and restricting the approved indication to men with documented low testosterone from identifiable medical conditions, not age-related decline alone.

The TRAVERSE Trial Resolution

The TRAVERSE trial (N=5,246), published in 2023 in the New England Journal of Medicine, randomized men aged 45 to 80 with hypogonadism and preexisting cardiovascular disease or elevated cardiovascular risk to transdermal testosterone gel or placebo 8. The primary endpoint of major adverse cardiovascular events (death, nonfatal MI, nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96, 95% CI 0.78 to 1.17). Non-inferiority was met.

The Endocrine Society's 2018 guideline, authored by Bhasin et al., recommends: "Clinicians should inform patients of the absence of definitive evidence regarding testosterone therapy and cardiovascular risk before initiating treatment" 10.

Venous Thromboembolism

TRAVERSE also identified a secondary signal: the incidence of pulmonary embolism was higher in the testosterone group (0.9% vs. 0.5%), though the overall venous thromboembolism composite did not reach statistical significance. The finding has prompted the Endocrine Society to recommend that clinicians discuss VTE risk with patients who have preexisting thrombophilic conditions.

AndroGel's Place in Current Clinical Practice

AndroGel remains available as both branded (1.62%) and generic (1%) formulations. It is no longer the only transdermal testosterone gel, but its trial evidence base is the deepest of any topical testosterone product.

Current Prescribing Patterns

Topical testosterone gels accounted for roughly 35% of testosterone prescriptions dispensed in the U.S. In 2024, with intramuscular testosterone cypionate regaining share due to lower cost. Among gels, generic testosterone 1% captures the majority of volume. Branded AndroGel 1.62% retains a niche among patients who prefer the smaller application volume or whose insurance formularies cover the branded product.

Monitoring Requirements

The Endocrine Society guideline recommends checking serum testosterone, hematocrit, and PSA at 3 to 6 months after initiation, then annually 10. Hematocrit above 54% requires dose reduction or temporary discontinuation. PSA velocity exceeding 1.4 ng/mL per year warrants urologic evaluation, though testosterone therapy has not been shown to increase prostate cancer incidence in randomized trials through follow-up periods of up to 3.5 years.

Prescribers initiating AndroGel or its generic equivalents should confirm morning total testosterone below 300 ng/dL on at least two separate measurements, identify a pathologic etiology when possible, and counsel patients on secondary transfer precautions including hand washing and covering the application site with clothing after the gel dries 10.